Substance monitoring and control in human or animal bodies

US9089305B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9089305-B2
Application numberUS-200913133335-A
CountryUS
Kind codeB2
Filing dateDec 8, 2009
Priority dateDec 9, 2008
Publication dateJul 28, 2015
Grant dateJul 28, 2015

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Diabetes management apparatus comprising a sensor providing measurements of glucose level in a human or animal; an insulin pump for delivering a dose of insulin to said human or animal; and a processor. The processor is adapted to perform the following steps: receive said measurements of glucose level from said sensor; calculate a insulin dose to be delivered by said insulin pump based on said received measurement; assess the validity of the status of the apparatus; and send a command to said insulin pump to deliver said calculated insulin dose, dependent on said assessing step confirming that the status is valid. The insulin pump is configured to deliver a preset dose of insulin unless said processor sends a command to said insulin pump and wherein a said command sent to said insulin pump is valid only for a predetermined time interval so that if no further commands are sent to said insulin pump during said predetermined time interval, said insulin pump reverts to delivering said preset dose of insulin at the end of said predetermined time interval.

First claim

Opening claim text (preview).

The invention claimed is: 1. A hybrid open and closed loop diabetes management apparatus comprising: a sensor providing measurements of glucose level in a human or animal when the apparatus is operating in a closed-loop mode for a predetermined time interval; an insulin pump for delivering both of: a preset dose of insulin to said human or animal when the apparatus is operating in an open-loop mode, wherein said open-loop mode is a default setting of said apparatus, and a calculated insulin dose to said human or animal when the apparatus is operating in said closed-loop mode for said predetermined time interval; and a processor which is adapted to perform the following steps: receive said measurements of glucose level from said sensor; calculate said calculated insulin dose to be delivered by said insulin pump in said closed-loop mode based on said received measurement; assess the validity of the status of the apparatus; and send a command to said insulin pump to enter said closed-loop mode for said predetermined time interval and deliver said calculated insulin dose during said predetermined time interval, dependent on said assessing step confirming that the status is valid, wherein said apparatus is configured to operate in said default open-loop mode wherein said insulin pump is configured to deliver said preset dose of insulin unless said processor sends said command to said insulin pump so that said apparatus is configured to operate in said closed-loop mode, and wherein the command sent to said insulin pump is valid only for said predetermined time interval so that if no further commands are sent to said insulin pump during said predetermined time interval, said insulin pump reverts to said open-loop mode delivering said preset dose of insulin at the end of said predetermined time interval. 2. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the preset dose is a pre-programmed continuous infusion rate of insulin and said processor is configured to send a command which alters said continuous infusion rate. 3. A hybrid open and closed loop diabetes management apparatus according to claim 2 , wherein the predetermined time interval has a duration of five, ten, fifteen, or eighteen minutes. 4. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the predetermined time interval has a duration of five, ten, fifteen, or eighteen minutes. 5. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the processor is configured to confirm the validity of the system by assessing whether or not the sensor is providing valid and/or not corrupted glucose measurements. 6. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the processor is configured to confirm the validity of the system by assessing whether or not the sensor is communicating correctly with the processor. 7. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the processor is configured to confirm the validity of the system by assessing whether or not the insulin pump is correctly delivering insulin. 8. A hybrid open and closed loop diabetes management apparatus according to claim 1 , comprising more than one sensor. 9. A hybrid open and closed loop diabetes management apparatus according to claim 8 , comprising a plurality of glucose sensors and wherein the processor is configured to confirm the validity of the system by assessing the concordance of the readings from the plurality of glucose sensors. 10. A hybrid open and closed loop diabetes management apparatus according to claim 8 , comprising a non-glucose sensor measuring a non-glucose substance and wherein the processor is configured to confirm the validity of the system by assessing the measurements from the non-glucose sensor. 11. A hybrid open and closed loop diabetes management apparatus according to claim 1 , wherein the processor is configured to confirm the validity of the system by determining the preferred operational mode for the time of day. 12. A hybrid open and closed loop diabetes management apparatus according claim 1 , further comprising a monitor for displaying information to a patient and/or for inputting information from a patient. 13. A hybrid open and closed loop diabetes management apparatus according to claim 12 , wherein said processor is integrated in said monitor. 14. A computer-implemented method of controlling a hybrid open and closed loop diabetes management apparatus, the method comprising the steps of: delivering both of: a pre-set dose of insulin to a human or animal when the apparatus is operating in an open-loop mode, wherein said open-loop mode is a default setting of said apparatus, and a calculated insulin dose to said human or animal when the apparatus is operating in a closed-loop mode for a predetermined time interval; controlling said delivery of insulin in said closed-loop mode by performing the following steps: calculating said calculated insulin dose to be delivered in said closed-loop mode based on measurements of glucose levels in said human or animal; performing a status integrity check; issuing a command to enter said closed-loop mode for said predetermined time interval and deliver said calculated insulin dose during said predetermined time interval, dependent on confirmation that said status integrity check is valid; wherein the issued command is valid only for said predetermined time interval so that if no further commands are issued during said predetermined time interval, said insulin delivery reverts to said open-loop mode delivering said preset dose of insulin at the end of said predetermined time interval. 15. A carrier carrying computer program code to, when running, implement the method of claim 14 .

Assignees

Inventors

Classifications

  • for measuring glucose, e.g. by tissue impedance measurement · CPC title

  • with a programmable infusion control system, characterised by the infusion program · CPC title

  • using feedback of body parameters, e.g. blood-sugar, pressure (measurement of body parameters A61B5/00) · CPC title

  • sublocal, e.g. between console and disposable · CPC title

  • Physics · mapped topic

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9089305B2 cover?
Diabetes management apparatus comprising a sensor providing measurements of glucose level in a human or animal; an insulin pump for delivering a dose of insulin to said human or animal; and a processor. The processor is adapted to perform the following steps: receive said measurements of glucose level from said sensor; calculate a insulin dose to be delivered by said insulin pump based on said …
Who is the assignee on this patent?
Hovorka Roman, Cambridge Entpr Ltd
What technology area does this patent fall under?
Primary CPC classification A61B5/4839. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).